Abstract
Hong Kong utilized an elimination strategy with intermittent use of public health and social measures and increasingly stringent travel regulations to control SARS-CoV-2 transmission. By analyzing >1700 genome sequences representing 17% of confirmed cases from 23-January-2020 to 26-January-2021, we reveal the effects of fluctuating control measures on the evolution and epidemiology of SARS-CoV-2 lineages in Hong Kong. Despite numerous importations, only three introductions were responsible for 90% of locally-acquired cases, two of which circulated cryptically for weeks while less stringent measures were in place. We found that SARS-CoV-2 within-host diversity was most similar among transmission pairs and epidemiological clusters due to a strong transmission bottleneck through which similar genetic background generates similar within-host diversity.
One sentence summary Out of the 170 detected introductions of SARS-CoV-2 in Hong Kong during 2020, three introductions caused 90% of community cases.
Competing Interest Statement
BJC has consulted for Roche, Sanofi Pasteur, GSK, AstraZeneca and Moderna. The authors declare no other competing interests.
Funding Statement
This study was partly supported by the Health and Medical Research Fund, Food and Health Bureau of the Hong Kong SAR Government (COVID190118), Collaborative Research Fund of the Research Grants Council of the Hong Kong SAR Government (C7123-20G) and National Institutes of Health (U01AI151810, HHSN272201400006C, 75N93021C00016)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW) (IRB No.UW 20-168)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Hong Kong SARS-CoV-2 genome sequences and associated metadata is deposited at gisaid.org. All anonymized data, sequence accession numbers, code, and analysis files are available in supplementary materials and in GitHub repository (https://github.com/hku-sph-covid-19-genomics-consortium/hk-sars-cov-2-genomic-epidemiology).
https://github.com/hku-sph-covid-19-genomics-consortium/hk-sars-cov-2-genomic-epidemiology
